Lead Sponsor

Exscientia AI Limited

Collaborators

Age

18 - 125 years

Sex

FEMALE

Healthy Volunteers

No

•Minimum age 18 years
•Signed informed consent form
•Confirmed diagnosis of ovarian cancer except low grade serous, clear cell and mucinous histology
•Where patients are treatment naïve, patients need to have disease stage FIGO (International Federation of Gynecology and Obstetrics) III or FIGO IV.
•Patient is expected to receive primary chemotherapy/maintenance after initial surgical debulking or a further line of systemic therapy in the relapsed setting according to treatment guidelines
•Feasibility of collecting malignant ascites and/or pleural effusion during either primary debulking surgery or a routine drainage procedure prior to initiation of the first or next line of systemic therapy
•ECOG (Eastern Cooperative Oncology Group) stage 0-2

•Previously study participation
•Known or suspected HIV or active Hepatitis B and/or C infection or active COVID-19 infection
•Anticancer treatment or radiation therapy of the region which is to be drained or biopsied within the last 4 weeks
•Patient unfit or not willing to receive any further systemic treatment
•Patient is treated with therapeutics not tested in the assay - with the exception of anti-VEGF (Vascular endothelial growth factor) therapy
•Known pregnancy
•Sample quality criteria are not met (at least 250ml of ascites available, no signes of bacterial superinfection, no additives, at least 1% EpCAM (Epithelial Cell Adhesion Molecule) positive cells, viability at least 60%)

Related studies

NCT07432633 · Colorectal Cancer, Epithelial Ovarian Cancer, and more

NCT06994195 · Epithelial Ovarian Cancer, Fallopian Tube Cancer, and more

NCT06915025 · Epithelial Ovarian Cancer, Ovarian Cancer, and more

NCT07480954 · Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, and more

NCT06412510 · Ovarian Cancer, Epithelial Ovarian Cancer, and more

Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer